Screening strategies for cardiovascular disease in asymptomatic adults

Primary Care - Clinics in Office Practice

Volumn 41, Issue 2, 2014, Pages 371-397

  Wallace, Margaret L ^a   Ricco, Jason A ^a   Barrett, Bruce ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Cardiovascular disease screening; Evidence based; General risk adult population; Primary care

Indexed keywords

C REACTIVE PROTEIN; HOMOCYSTEINE; LIPID; LIPOPROTEIN;

ABDOMINAL AORTA; AGE; ARTERIAL WALL THICKNESS; ASIAN AMERICAN; ASYMPTOMATIC DISEASE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BEHAVIOR; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY CALCIUM SCORE; DIAGNOSTIC TEST; ELECTROCARDIOGRAPHY; ENVIRONMENTAL FACTOR; EUROPEAN AMERICAN; EVIDENCE BASED MEDICINE; FAMILY HISTORY; GENETIC SCREENING; GENETICS; HIGH RISK POPULATION; HISPANIC; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCREENING TEST; SMOKING; ULTRASOUND; UNITED STATES; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CAROTID ARTERY; ECHOGRAPHY; GENETIC PREDISPOSITION; MASS SCREENING; ORGANIZATION AND MANAGEMENT; PRIMARY HEALTH CARE; PROCEDURES; RISK FACTOR;

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; ELECTROCARDIOGRAPHY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIPIDS; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; RISK ASSESSMENT; RISK FACTORS;

EID: 84900007118     PISSN: 00954543     EISSN: 1558299X     Source Type: Journal    
DOI: 10.1016/j.pop.2014.02.010     Document Type: Review

References (101)

1. Kochanek K.D., Xu J., Murphy S.L., et al. Deaths: final data for 2009. Natl Vital Stat Rep 2011, 60(3):1-17.
2. Centers for Disease Control and Prevention Heart disease and stroke prevention addressing the nation's leading killers: at a glance 2011. Prev Chronic Dis 2011, Available at:, Accessed May 16, 2013. http://www.cdc.gov/chronicdisease/resources/publications/aag/dhdsp.htm.
3. Cosford P.A., Leng G.C. Screening for abdominal aortic aneurysm. Cochrane Database Syst Rev 2011, (2). [review], CD002945.
4. Fleming C., Whitlock E., Beil T., et al. Screening for abdominal aortic aneurysm: a best-evidence systematic review for the US Preventive Service Task Force. Ann Intern Med 2005, 142:203-211.
5. Khot U.N., Khot M.B., Bajzer C.T., et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003, 290(7):898-904.
6. Harold J.G., Williams K.A. President's page: disparities in cardiovascular care: finding ways to narrow the gap. JAm Coll Cardiol 2013, 62(6):563-565.
7. Ford E.S. Trends in predicted 10-year risk of coronary heart disease and cardiovascular disease among U.S. adults from 1999 to 2010. JAm Coll Cardiol 2013, 61(22):2249-2252.
8. Drewnowski A. Obesity, diets, and social inequalities. Nutr Rev 2009, 67(Suppl 1):S36-S39.
9. Expert Panel on Detection Evaluation, Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285(19):2486-2497.
10. Wood D., De Backer G., Faergeman O., et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998, 140(2):199-270.
11. Califf R.M., Armstrong P.W., Carver J.R., et al. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. JAm Coll Cardiol 1996, 27(5):1007-1019.
12. Matheny M., McPheeters M., Glasser A., et al. Systematic review of cardiovascular disease risk assessment tools. Evidence Synthesis No. 85 2011, AHRQ Publication, Rockville (MD).
13. Barratt A., Wyer P.C., Hatala R., et al. Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ 2004, 171(4):353-358.
14. Goff D.C., Lloyd-Jones D.M., Bennett G., et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013, [Epub ahead of print].
15. James P.A., Oparil S., Carter B.L., et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014, 311(5):507-520.
16. Sheridan S., Pignone M., Donahue K. Screening for high blood pressure: a review of the evidence for the U.S. Preventive Services Task Force. Am J Prev Med 2003, 25(2):151-158.
17. US Preventive Services Task Force Screening for high blood pressure: US Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2007, 147(11):783-786.
18. Di Angelantonio E., Sarwar N., Perry P., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302(18):1993-2000. Emerging Risk Factors Collaboration.
19. Akhabue E., Thiboutot J., Cheng J.W., et al. New and emerging risk factors for coronary heart disease. Am J Med Sci 2014, 347(2):151-158.
20. Humphrey L.L., Fu R., Rogers K., et al. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc 2008, 83(11):1203-1212.
21. O'Leary D.H., Polak J.F., Kronmal R.A., et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. NEngl J Med 1999, 340(1):14-22.
22. Chambless L.E., Heiss G., Folsom A.R., et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997, 146(6):483-494.
23. Spence J.D. Technology insight: ultrasound measurement of carotid plaque-patientmanagement, genetic research, and therapy evaluation. Nat Clin Pract Neurol 2006, 2(11):611-619.
24. Pletcher M.J., Tice J.A., Pignone M., et al. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Intern Med 2004, 164(12):1285-1292.
25. Kramer C.K., Zinman B., Gross J.L., et al. Coronary artery calcium score prediction of all cause mortality and cardiovascular events in people with type 2 diabetes: systematic review and meta-analysis. BMJ 2013, 346:f1654.
26. Moyer V.A., US Preventive Serivces Task Force Screening for coronary heart disease with electrocardiography: US Preventive Services Task Force recommendation statement. Ann Intern Med 2012, 157(7):512-518.
27. Ashley E.A., Raxwal V.K., Froelicher V.F. The prevalence and prognostic significance of electrocardiographic abnormalities. Curr Probl Cardiol 2000, 25(1):1-72.
28. Cirino A.L., Ho C.Y. Genetic testing for inherited heart disease. Circulation 2013, 128(1):e4-e8.
29. Liao Y., McGee D.L., Cooper R.S., et al. How generalizable are coronary risk prediction models? Comparison of Framingham and two national cohorts. Am Heart J 1999, 137(5):837-845.
30. Orford J.L., Sesso H.D., Stedman M., et al. Acomparison of the Framingham and European Society of Cardiology coronary heart disease risk prediction models in the normative aging study. Am Heart J 2002, 144(1):95-100.
31. Okwuosa T.M., Greenland P., Ning H., et al. Yield of screening for coronary artery calcium in early middle-age adults based on the 10-year Framingham Risk Score: the CARDIA study. JACC Cardiovasc Imaging 2012, 5(9):923-930.
32. Ridker P.M., Cook N.R. Statins: new American guidelines for prevention of cardiovascular disease. Lancet 2013, 382(9907):1762-1765.
33. Goff D.C., Lloyd-Jones D.M., Bennett G., et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JAm Coll Cardiol 2013, [Epub ahead of print].
34. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 1989, 129(4):687-702.
35. Fried L.P., Borhani N.O., Enright P., et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991, 1(3):263-276.
36. Friedman G.D., Cutter G.R., Donahue R.P., et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. JClin Epidemiol 1988, 41(11):1105-1116.
37. Govindaraju D.R., Cupples L.A., Kannel W.B., et al. Genetics of the Framingham Heart Study population. Adv Genet 2008, 62:33-65.
38. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97(18):1837-1847.
39. Assmann G., Cullen P., Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002, 105(3):310-315.
40. Conroy R.M., Pyorala K., Fitzgerald A.P., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003, 24(11):987-1003.
41. Taylor F., Huffman M.D., Macedo A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013, (1). CD004816.
42. Pignone M.P., Phillips C.J., Atkins D., et al. Screening and treating adults for lipid disorders. Am J Prev Med 2001, 20(3 Suppl):77-89.
43. Helfand M., Carson S. Screening for lipid disorders in adults: selective update of 2001 US Preventive Services Task Force Review. Evidence synthesis no. 49 2008, AHRQ Publication, Rockville (MD).
44. National Cholesterol Education Program Expert Panel on Detection Evaluation, Treatment of High Blood Cholesterol in Adults Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106(25):3143-3421.
45. Stone N.J., Robinson J., Lichtenstein A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013, [Epub ahead of print].
46. Mihaylova B., Emberson J., Blackwell L., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380(9841):581-590.
47. Taylor F., Ward K., Moore T.H., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011, (1). CD004816.
48. Cooper A., O'Flynn N. Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance. BMJ 2008, 336(7655):1246-1248.
49. Abramson J.D., Rosenberg H.G., Jewell N., et al. Should people at low risk of cardiovascular disease take a statin?. BMJ 2013, 347:f6123.
50. Mosca L., Benjamin E.J., Berra K., et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. Circulation 2011, 123(11):1243-1262.
51. Helfand M., Buckley D., Freeman M., et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the US Preventive Services Task Force. Ann Intern Med 2009, 151:496-507.
52. Helfand M., Buckley D., Fleming C., et al. Screening for intermediate risk factors for coronary heart disease: systematic evidence synthesis. Evidence synthesis No. 73 2009, AHRQ Publication, Rockville (MD).
53. Buckley D.I., Fu R., Freeman M., et al. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the US Preventive Services Task Force. Ann Intern Med 2009, 151(7):483-495.
54. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002, 288(16):2015-2022. Homocysteine Studies Collaboration.
55. Bonaa K.H., Njolstad I., Ueland P.M., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. NEngl J Med 2006, 354(15):1578-1588.
56. Lonn E., Yusuf S., Arnold M.J., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. NEngl J Med 2006, 354(15):1567-1577.
57. Schnyder G., Roffi M., Flammer Y., et al. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA 2002, 288(8):973-979.
58. Kavousi M., Elias-Smale S., Rutten J.H., et al. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med 2012, 156(6):438-444.
59. van Kempen B.J., Spronk S., Koller M.T., et al. Comparative effectiveness and cost-effectiveness of computed tomography screening for coronary artery calcium in asymptomatic individuals. JAm Coll Cardiol 2011, 58(16):1690-1701.
60. Chou R., Arora B., Dana T., et al. Screening asymptomatic adults with resting or exercise electrocardiography: a review of the evidence for the US Preventive Services Task Force. Ann Intern Med 2011, 155:375-385.
61. Austin M.A., Hutter C.M., Zimmern R.L., et al. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004, 160(5):407-420.
62. Wonderling D., Umans-Eckenhausen M.A., Marks D., et al. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. Semin Vasc Med 2004, 4(1):97-104.
63. Nherera L., Marks D., Minhas R., et al. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart 2011, 97(14):1175-1181.
64. United States Preventive Services Task Force. US Preventive Services Task Force. 2013. Available at:. Accessed October 21, 2013. http://www.uspreventiveservicestaskforce.org/.
65. US Preventive Services Task Force. US Preventive Services Task Force grade definitions. 2012. Available at:. Accessed May 23, 2013. http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm.
66. Greenland P., Alpert J.S., Beller G.A., et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JAm Coll Cardiol 2010, 56(25):e50-e103.
67. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289(19):2560-2572.
68. National Cholesterol Education Program-NHLBI, NIH. 2013. Available at:. Accessed October 21, 2013. http://www.nhlbi.nih.gov/about/ncep/.
69. Minhas R., Humphries S.E., Qureshi N., NICE Guideline Development Group, et al. Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia. Heart 2009, 95(7):584-587. [discussion: 587-91].
70. US Preventive Services Task Force. Screening for high blood pressure: US Preventive Services Task Force reaffirmation recommendation statement. 2007. Available at:. Accessed January 2, 2014. http://www.uspreventiveservicestaskforce.org/uspstf07/hbp/hbprs.htm.
71. U.S Preventive Services Task Force. Recommendations and rationale: screening for lipid disorders in adults. 2008. Available at:. Accessed May 23, 2013. http://www.uspreventiveservicestaskforce.org/uspstf08/lipid/lipidrs.htm.
72. US Preventive Services Task Force Using nontraditional risk factors in coronary heart disease risk assessment: US Preventive Services Task Force recommendation statement. Ann Intern Med 2009, 151:474-482.
73. Lim L.S., Haq N., Mahmood S., et al. Atherosclerotic cardiovascular disease screening in adults: American College of Preventive Medicine position statement on preventive practice. Am J Prev Med 2011, 40(3):381.e1-381.e10.
74. US Preventive Services Task Force Screening for abdominal aortic aneurysm: recommendation statement. Ann Intern Med 2005, 142:198-202.
75. US Preventive Services Task Force. Screening for coronary heart disease: recommendation statement. 2004. Available at:. Accessed May 23, 2013. http://www.uspreventiveservicestaskforce.org/3rduspstf/chd/chdrs.htm.
76. McCall-Hosenfeld J.S., Weisman C.S., Camacho F., et al. Multilevel analysis of the determinants of receipt of clinical preventive services among reproductive-age women. Womens Health Issues 2012, 22(3):e243-e251.
77. Ma J., Stafford R.S. Screening, treatment, and control of hypertension in US private physician offices, 2003-2004. Hypertension 2008, 51(5):1275-1281.
78. Solberg L.I., Kottke T.E., Brekke M.L. Variation in clinical preventive services. Eff Clin Pract 2001, 4(3):121-126.
79. Bertoni A.G., Bonds D.E., Steffes S., et al. Quality of cholesterol screening and management with respect to the National Cholesterol Education's Third Adult Treatment Panel (ATPIII) guideline in primary care practices in North Carolina. Am Heart J 2006, 152(4):785-792.
80. Rifas-Shiman S.L., Forman J.P., Lane K., et al. Diabetes and lipid screening among patients in primary care: a cohort study. BMC Health Serv Res 2008, 8:25.
81. Barham A.H., Goff D.C., Chen H., et al. Appropriateness of cholesterol management in primary care by sex and level of cardiovascular risk. Prev Cardiol 2009, 12(2):95-101.
82. Allison M.A., Ho E., Denenberg J.O., et al. Ethnic-specific prevalence of peripheral arterial disease in the United States. Am J Prev Med 2007, 32(4):328-333.
83. Rowe V.L., Weaver F.A., Lane J.S., et al. Racial and ethnic differences in patterns of treatment for acute peripheral arterial disease in the United States, 1998-2006. JVasc Surg 2010, 51(4 Suppl):21S-26S.
84. Stewart S.H., Silverstein M.D. Racial and ethnic disparity in blood pressure and cholesterol measurement. JGen Intern Med 2002, 17(6):405-411.
85. Vaidya V., Partha G., Howe J. Utilization of preventive care services and their effect on cardiovascular outcomes in the United States. Risk Manag Healthc Policy 2011, 4:1-7.
86. Nelson K., Norris K., Mangione C.M. Disparities in the diagnosis and pharmacologic treatment of high serum cholesterol by race and ethnicity: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2002, 162(8):929-935.
87. Ford E.S., Li C., Pearson W.S., et al. Trends in hypercholesterolemia, treatment and control among United States adults. Int J Cardiol 2010, 140(2):226-235.
88. Ferrante J.M., Balasubramanian B.A., Hudson S.V., et al. Principles of the patient-centered medical home and preventive services delivery. Ann Fam Med 2010, 8(2):108-116.
89. Stafford R.S., Misra B. Variation in routine electrocardiogram use in academic primary care practice. Arch Intern Med 2001, 161(19):2351-2355.
90. Rabinowitz I., Tamir A. The SaM (Screening and Monitoring) approach to cardiovascular risk-reduction in primary care-cyclic monitoring and individual treatment of patients at cardiovascular risk using the electronic medical record. Eur J Cardiovasc Prev Rehabil 2005, 12(1):56-62.
91. Linder J.A., Ma J., Bates D.W., et al. Electronic health record use and the quality of ambulatory care in the United States. Arch Intern Med 2007, 167(13):1400-1405.
92. Romano M.J., Stafford R.S. Electronic health records and clinical decision support systems: impact on national ambulatory care quality. Arch Intern Med 2011, 171(10):897-903.
93. Hivert M.F., Grant R.W., Shrader P., et al. Identifying primary care patients at risk for future diabetes and cardiovascular disease using electronic health records. BMC Health Serv Res 2009, 9:170.
94. Walsh M.N., Yancy C.W., Albert N.M., et al. Electronic health records and quality of care for heart failure. Am Heart J 2010, 159(4):635-642.e1.
95. Zhou L., Soran C.S., Jenter C.A., et al. The relationship between electronic health record use and quality of care over time. JAm Med Inform Assoc 2009, 16(4):457-464.
96. Kaiser Family Foundation. Health reform implementation timeline. Health Reform 2013. Available at:. Accessed August 7, 2013. http://kff.org/interactive/implementation-timeline/.
97. US Preventive Services Task Force. Affordable Care Act: A and B recommendations for preventive services. 2013. Available at:. Accessed January 2, 2014. http://www.uspreventiveservicestaskforce.org/uspstf/uspsabrecs.htm.
98. Berwick D.M. Launching accountable care organizations-the proposed rule for the Medicare Shared Savings Program. NEngl J Med 2011, 364(16):e32.
99. Quality Measurement & Health Assessment Group Center for Medicare and Medicaid Services. Quality performance standards narrative measure specifications. Accountable Care Organization 2013 Program Analysis. 2012. Available at:. Accessed August 8, 2013. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/sharedsavingsprogram/Downloads/ACO-NarrativeMeasures-Specs.pdf.
100. American Academy of Family Physicians Joint principles of the Patient-Centered Medical Home. Del Med J 2008, 80(1):21-22.
101. Krogsboll L., Jorgensen K., Gronhoj L., et al. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database Syst Rev 2012, (10). [review], CD009009.